Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Gilead
 More »

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and ... And Gilead Sciences also announced results from a Phase II study, a trial evaluating its ...
    5-16-2013
  • Biotechs Need to Walk the Walk on Drug Value
    ... Another precompetitive effort, DILI-sim Initiative, joins the Hamner Institutes for Health Sciences with 12 drug developers-Amgen, AZ, BMS, Eli Lilly, Gilead, Glaxo, Janssen, ...
    5-15-2013
  • GEN | Biolinks
    ... Georgetown University Georgia Bio Georgia Department of Economic Development Geron Gilead Sciences Gilson GlaxoSmithKline Global Alliance for TB Drug Development GlobeImmune ...
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    ... Another precompetitive effort, DILI-sim Initiative, joins the Hamner Institutes for Health Sciences with 12 drug developers-Amgen, AZ, BMS, Eli Lilly, Gilead, Glaxo, Janssen, ...
    4-22-2013
  • CEO Perks
    ... $2.982 million John C. Martin Gilead Sciences, chairman and CEO Perks and "all ... of our executive compensation program," Gilead stated in its proxy statement, filed ...
    4-12-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    ... tenofovir disoproxil fumarate) 2012 sales: $57.536 million 14 Marketer(s): Gilead Sciences Indication(s): HIV-1 infection in adults who are antiretroviral ...
    4-4-2013
  • Top 20 Biopharma R&D Spenders
    looking to expand their product offerings (Gilead), or pharma giants scrambling to replenish pipelines depleted by patent-cliff expirations (AstraZeneca, Bristol-Myers Squibb). ...
    4-1-2013
  • Top 20 Best-Selling Drugs of 2012
    disoproxil fumarate) Drug maker: Gilead Sciences Indication(s): HIV-1 infection ... emtricitabine, and tenofovir) Drug maker: Gilead Sciences Indication(s): HIV-1 infection ...
    3-1-2013
  • Elan Cool to Royalty Pharma Offer
    With $3.25 billion coming its way from selling its 50% share in the multiple sclerosis drug Tysabri, Elan has suddenly attracted a would-be suitor looking to buy the company for ...
    2-25-2013
  • Adimab Inks Double Deals with Merck & Lilly
    Over the past three years, Adimab has established collaborations with Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, and Kyowa Hakko ...
    1-8-2013
  • Gilead Earmarks Over $115M in MacroGenics Deal
    MacroGenics entered into a license agreement with Gilead Sciences for the development and ... Gilead has exclusive worldwide rights for three of the programs. For one program, ...
    1-7-2013
  • Top 25 M&A Deals of 2012
    deal. #25. YM Biosciences Acquired by: Gilead Sciences Price: $510 million Deal ... Premium: N/A #1. Pharmasset Acquired by: Gilead Sciences Price: $11.2 billion Deal ...
    1-4-2013
  • Gilead Expands Pipeline With $510M YM Purchase
    Gilead Sciences will buy YM BioSciences for about $510 million, the companies said today, ... the second half of the coming year, Gilead said, it plans to launch a pivotal Phase ...
    12-12-2012
  • Biotech: A Model of Creative Acquisition
    ... The four companies that were among the top ten in both 2005 and 2011-Amgen, Gilead, Biogen Idec, and Celgene-reported total revenues and total net income of $17 billion and $4.7 ...
    12-1-2012
  • 25 Diabetes Drugs in the Pipeline Right Now
    ... peripheral neuropathy (extended release formulation) Ranolazine Sponsor/Developer: Gilead Mechanism of action: Late sodium current inhibitor Indication (Phase): Type 2 diabetes ...
    11-30-2012

  • Journal Articles

  • The Balm of Gilead Project: A Demonstration Project on End-of...
    Elizabeth A. Kvale, Beverly R. Williams, James L. Bolden, Carol G. Padgett, F. Amos Bailey
    Journal of Palliative Medicine
    The Balm of Gilead Project: A Demonstration Project on End-of-Life Care for Safety-Net Populations Journal of Palliative Medicine The Balm of Gilead is a comprehensive program of ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll